Ho Wah Genting Berhad (KLSE:9601) ventures into healthcare industry and exploring into biotech investment opportunities in USA
Ho Wah Genting Berhad (KLSE:9601)has recently proposed diversification of its existing
businesses to include healthcare-related businesses such as biotechnology, health
supplement and healthcare technology sub-segment.
“The global healthcare market reached a value of nearly
$8,452 billion in 2018, having grown at a compound annual growth rate (CAGR) of
7.3% since 2014, and is expected to grow at a CAGR of 8.9% to nearly $11,908.9
billion by 2022 . Besides, prospects in the healthcare-related business are
positive due to the favourable outlook on the healthcare industry in Malaysia.
The Malaysian healthcare industry in terms of expenditures in 2019 is estimated
at RM63.94 billion and is projected to grow at a compound annual growth rate
(“CAGR”) of 7.5% to RM91.40 billion in 2024.”
As the COVID-19 continues, demand for healthcare
products and services related to COVID-19 pandemic are expected to drive the
growth of the healthcare industry for the short and medium term (2020-2022).
The above insights gave birth to the group's
portfolio which comprises of its premium healthcare businesses as follows:
HWGB BioTech aims to provide a
comprehensive range of big health products and solutions that adopts a
preventive measure readily available to improve the livelihood of Malaysians.
Currently, there are two main
products under its biotech businesses, namely the Lionrun Shanghai Liangrun
antibody IgM/IgG Covid-19 diagnostic test kit and the newly-launched D’VIRIA
Nano CD disinfectant.
In May this year, HWGB BioTech has been appointed as the authorised
distributor of antibody IgM/IgG Covid-19 diagnostic kit in Malaysia by Shanghai
Liangrun Biomedicine Technology Co Ltd. The company had also submitted an
application to the Ministry of Health for the certification of the diagnostic
kit and is currently pending approval. Further, HWGB BioTech had on May 15 appointed
PM Care Sdn Bhd as the non-exclusive sub-distributor for the distribution of
the diagnostic kit.
Shanghai Liangrun is one of the
high-tech biological companies focusing on tumor and infectious disease
diagnostics in China. While PM Care is the pioneer and leading third-party
administrator (TPA) in Malaysia in collaboration with a network of more than
3,500 medical providers nationwide. PM Care is a 90.0% owned subsidiary of
Sumitomo Corporation, Japan (TYO:8053).
The Lionrun Shanghai Liangrun antibody
IgM/IgG Covid-19 diagnostic test kit is a CE and FDA-certified product with
high sensitivity and specificity of up to 90% which delivers fast result in 10
minutes. The Covid-19 IgG/IgM is a rapid test intended for the presumptive
qualitative detection of IgM/IgG antibodies from the Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in blood samples from individuals with
signs and symptoms of infection who are suspected of Covid-19. It provides
early discovery - positive IgM indicate early phase of infection, and safety -
individual test avoid cross-infection.
Besides the rapid test kit, the group is now also focusing on
its newly-launched TwinOxide® product which carries the
brand name of “D’VIRIA - disinfectant against virus & bacteria”. Dviria Nano Tech Sdn Bhd has recently been appointed
as the exclusive distributor of Twin Oxide Southeast Asia Sdn
Bhd (“Twin Oxide”) for the distribution of its TwinOxide®
products in Malaysia and Indonesia retail segment.
The principal activities of Dviria is to carry
on in the business in sanitising and disinfecting machines, equipment,
apparatus including the sanitising, disinfecting agents, raw materials,
products and parts.
Dviria Nano Tech Sdn Bhd, we are proud to be in an
exclusive partnership with Twin Oxide
Southeast Asia Sdn Bhd to bring you an exciting new
benchmark on disinfection processes.”
D’VIRIA Nano CD disinfectant is a
revolutionary, advanced delivery system to generate a highly pure aqueous
chlorine dioxide solution that does not contain any chlorine compounds and has
removed all known drawbacks, side-effects and by-products known from chlorine
dioxide. It is a patented formula from the Netherlands and also NSF
International USA, OMRI listed and Halal certified. Tested non-toxic,
non-corrosive, non-irritating to skin, non-carcinogenic or non-harmful to the
environment, D’VIRIA Nano CD disinfectant has the fastest kill time (in
seconds) with minimum quantity compared to other disinfectants in the market
which takes minutes or hours.
“Chlorine dioxide (CD) is the active
ingredient of D’VIRIA Nano CD disinfectant. What makes us unique is it
does not generate bi-products unlike the traditional chlorine dioxide as we
As for its
health supplement segment, HWGB had in February 2020 appointed Guardion
(Nasdaq: GHSI) to design and manufacture an exclusive custom immune support
nutraceutical formula (nutraceutical product may be defined as a substance,
which has physiological benefit or provides protection against chronic
disease). Guardion (Nasdaq: GHSI) will adopt the exclusive custom immune
support nutraceutical formula in the development of daily dietary supplement
that is designed to strengthen the immune system and provide both
anti-inflammatory and antioxidant benefits to the users. It also benefits the
(Nasdaq: GHSI) is a company listed on the Nasdaq stock market and principally
involved in health sciences business such as development, formulation and
distribution of consumable medical products. It is a reputable medical company
backed by a globally respected Scientific and Medical Advisory Board.
Sdn Bhd was then incorporated in March this year to engage in the business of
trading and sales of nutraceutical products, dietary supplements and functional
Earlier, HWGB Biotech division engaged
Jeffrey Qiong Li, the principal lawyer of Foster Garvey PC to help exploring
business opportunities in the US healthcare industry. Besides, its chief
consultant committee is also venturing into biotech investment in the US. The
company’s chief consultant committee is composed of experts in the field of
health technology, medical, sales and marketing strategies, and healthcare
related laws and regulations.